Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.
Jones James, Lucey Rebecca, Corrie Pippa·Pigment cell & melanoma research
BRAF-mutant melanoma patients can theoretically access both immunotherapy and BRAF-targeted therapy as treatment for metastatic disease. BRAF-targeted therapy is increasingly used 1st line for poorer prognostic patients, so we wanted to assess realistic expectations of these patients accessing 2nd-line immunotherapy. W…